Items tagged with Treatment
TB therapy does not affect ART response in South African children (post)
Receiving therapy for tuberculosis when starting a first antiretroviral therapy (ART) regimen did not affect virologic or CD4 response to that regimen in a study of 199 South African children. Responses appeared to be worse with lopinavir/ritonavir than with efavirenz in children taking TB therapy when ART began.
Sanofi receives FDA approval of Priftin® (rifapentine) tablets for the treatment of latent tuberculosis infection (post)
Following a priority review, the U.S. Food and Drug Administration has approved Priftin® (rifapentine) in combination with isoniazid (INH) for a new indication for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB) disease. Approved in the United States since 1998, Priftin is an antimycobacterial used in combination with one or more antituberculosis drugs for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis.
Treatment outcomes in HIV positive and negative people with drug resistant TB in Khayelitsha, Cape Town (post)
An analysis of treatment outcomes in HIV positive and negative people with drug resistant (DR) tuberculosis (TB) in Khayelitsha showed similar treatment success and long-term mortality in the presence of ART.
Anemia of inflammation often resolved after TB treatment (post)
Chemotherapy for tuberculosis resulted in significant reductions in anemia of inflammation, but had no effect on iron-deficiency anemia or multifactorial anemia, according to researchers from Cornell University.
CPTR workshop 2014 overview (post)
CPTR Workshop 2014 Overview
September 22-25, 2014
Omni Shoreham Hotel, Washington, DC
Anti-diabetic drug springs new hope for tuberculosis patients (post)
SINGAPORE, Dec 17, 2014 - A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing drug resistance.
Isoniazid, d-drugs, weight, boost neuropathy risk in African trial (post)
Isoniazid, stavudine (d4T), didanosine (ddI), higher weight, and older age all raised the risk of peripheral neuropathy in adults starting antiretroviral therapy (ART) in Uganda and Zimbabwe. Gender and pre-ART CD4 count did not affect chances of neuropathy in these DART trial participants.
New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency (post)
While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. New research conducted at the Center for Tuberculosis Research at the Johns Hopkins University School of Medicine shows that lower doses of the toxic drug bedaquiline — given together with verapamil, a medication that’s used to treat various heart conditions — can lead to the same antibacterial effects as higher toxic doses of bedaquiline. The combination of the two drugs could potentially shorten treatment time, reduce the side effects of bedaquiline and improve patient outcomes for those suffering from TB.
Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios (post)
New experimental evidence on anti-TB regimes based on low-efficacious linezolid dosage to treat XDR-TB patients
Page 8 of 108 · Total posts: 0
←First 7 8 9 Last→